A male patient underwent an aquablation procedure for symptomatic benign prostatic hyperplasia (bph).Procept biorobotics corporation (procep) became aware that two (2) weeks post aquablation procedure the patient is experiencing incontinence.Per manufacturer instructions for use, incontinence or overactive bladder is a potential risk of the aquablation procedure.No malfunction of the aquabeam robotic system was reported during this event.Procept has requested additional information regarding this event, including course of treatment taken with the patient.
|
The aquabeam robotic system was not returned for investigation of this event and is currently in use at the user facility.The investigation consisted of a review of the information reported to procept, plus a review of the event log files, device history record (dhr), and labeling.A review of the device history record (dhr) ab2000-b/serial number (b)(6) was conducted, which confirmed that there were no non-conformances, failures, discrepancies, or missed steps during the manufacturing process that could be related to the reported event.The review indicated that the system met all design and manufacturing specifications when released for distribution.The aquabeam robotic system instructions for use (ifu), ifu0101-00, rev.E, was reviewed and states the following: 4.3.Warnings: procedure as with any surgical urologic procedure, potential perioperative risks of the aquablation procedure include: incontinence or overactive bladder.A root cause for the reported event could not be determined.Three good-faith efforts were made to obtain the log files without success.The aquabeam robotic system instructions for use list incontinence or overactive bladder as a potential risk of the aquablation procedure.Based on the review of the dhr and ifu this event is considered not to be device-related.Submission of this report does not constitute an admission that the manufacturer's product caused or contributed to the event.
|